The endothelin axis: emerging role in cancer

Abstract
Studies have demonstrated the role of the ET axis in a wide variety of diseases, including cancer. ETA-receptor activation by ET-1 contributes to tumour growth and progression, inducing cell proliferation, survival, angiogenesis and metastatic spread, indicating that ETA-receptor blockade might improve cancer treatment. In Phase I and II clinical studies, ETA-receptor antagonists can be administered orally, once a day, and have a favourable tolerability profile. Preliminary data from clinical trials are promising. Studies are underway to better define the role and ET-receptor antagonists in the treatment of malignant diseases.